Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886648 | 0.86 | SSTR3 (0.43) | ALDH1A1MAPT | |
| SCHEMBL15113709 | 0.83 | MME (0.38) | CNR1CNR2ADORA1 | |
| SCHEMBL15106086 | 0.82 | JAK2 (0.31) | — | |
| SCHEMBL20221405 | 0.82 | KEAP1 (0.36) | CNR1CNR2ALDH1A1PDE2AKDM4E | |
| SCHEMBL20054469 | 0.82 | CNR1 (0.35) | CNR1CNR2ADORA1PDE2ATACR3 | |
| SCHEMBL15114300 | 0.82 | CNR1 (0.35) | CNR1CNR2ADORA1PDE2ATACR3 | |
| SCHEMBL20054353 | 0.82 | CNR1 (0.35) | CNR1CNR2ADORA1PDE2ATACR3 | |
| SCHEMBL15114299 | 0.82 | CNR1 (0.35) | CNR1CNR2ADORA1PDE2ATACR3 | |
| SCHEMBL20054354 | 0.82 | CNR1 (0.35) | CNR1CNR2ADORA1PDE2ATACR3 | |
| SCHEMBL21245238 | 0.82 | ADORA1 (0.43) | ADORA1ADORA3ADORA2AADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305294-B1 | IMIDAZOLYL DERIVATIVES | SOD CONSEILS RECH APPLIC (FR) | 2007-04-25 | — | — | EP | claimed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2007-08-02 | — | — | US | disclosed |
| US-20070021390-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SCRAS | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021390-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, COMT | CNR1 400/4885CNR2 339/4885ADORA1 424/4885 |
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, SDHA | CNR1 432/4885CNR2 350/4885ADORA1 819/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | CNR1 17/4885CNR2 27/4885ADORA1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.